Company Profile

Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Companyâ€™s lead clinical-stage, oral kinase inhibitor tuspetinib (TUS) has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of anti-cancer therapies and regimens without overlapping toxicities. Its Luxeptinib (LUX) is being developed for the treatment of patients with certain B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and certain non-Hodgkinâ€™s lymphomas (NHL) who are resistant or intolerant to conventional treatments.

Employees

Sector

Pharmaceuticals

More about the company

02/07	Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences	MT
30/06	Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc..	CI
15/06	Aptose Biosciences Inc. Presents Safety, Response and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML	CI
15/06	Aptose Biosciences Updated Tuscany Trial Data Reported in Oral Presentation at EHA 2026	MT
29/05	Aptose Biosciences Says Acquisition by Hanmi Delayed Until June	MT
29/05	Aptose Biosciences says closing of arrangement with Hanmi Pharmaceutical further delayed	RE
14/05	Aptose Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
01/04	Aptose Shareholders Approve Acquisition By Hanmi Pharmaceutical in "Go Private" Transaction	MT
01/04	Aptose Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01/04	Aptose Biosciences Inc. - Shareholder/Analyst Call
31/03	Aptose Biosciences Inc. Auditor Raises 'Going Concern' Doubt	CI
23/03	Leading independent proxy advisory firm Glass Lewis endorses Aptose plan of arrangement	RE
23/03	Aptose Biosciences Brief: Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement With Hanmi Pharmaceutical	MT

19/03	Leading independent proxy advisory firm ISS recommends Aptose Biosciences shareholders vote "for" proposed plan of arrangement with Hanmi Pharmaceutical	RE
19/03	Aptose Brief: Independent Proxy Advisory Firm ISS Recommends Aptose Shareholders Vote "FOR" Proposed Plan of Arrangement with Hanmi Pharmaceutical	MT
11/06/24	HC Wainwright Adjusts Price Target on Aptose Biosciences to $7 From $23, Maintains Buy Rating	MT
10/11/23	RBC Cuts Price Target on Aptose Biosciences to $18 From $23, Keeps Outperform, Speculative Risk	MT
11/08/23	Oppenheimer Adjusts Aptose Biosciences Price Target to $15 From $50, Maintains Outperform Rating	MT

01/07	Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical	AQ
15/06	Aptose Biosciences : Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	PU
15/06	Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation	AQ
29/05	Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical	AQ
14/05	Aptose Biosciences: Q1 Earnings Snapshot	AQ

06/12	Tokenización: ¿Va a cambiar tanto la vida de los inversores?
06/12	Universo cripto: la tokenizzazione cambierà davvero la vita degli investitori?
09/09/23	Vastzetting: Ethereum scheert hoge toppen - cryptonieuws
08/09/23	Staking: Ethereum raggiunge nuove vette - Resoconto Cripto

Manager	Title	Age	Since
C. Payne DFI	Director of Finance/CFO	63	27/06/2022
Victor Montalvo-Lugo CTO	Chief Tech/Sci/R&D Officer	-	01/11/2019
Rafael Bejar CTO	Chief Tech/Sci/R&D Officer	54	01/01/2020

Aptose Biosciences Stock Nasdaq

Stocks

Pharmaceuticals

Latest news : Aptose Biosciences

Last Transcript : Aptose Biosciences

Analysts' recommendations : Aptose Biosciences

Press Releases : Aptose Biosciences

News in other languages : Aptose Biosciences

Quotes and Performance

Managers and Directors : Aptose Biosciences

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APTOSE BIOSCIENCES	-7.92%	+21.79%	-	-	4.32M
ELI LILLY AND COMPANY	+1.24%	-2.45%	+50.76%	+90.01%	1,002B
JOHNSON & JOHNSON	+0.07%	-2.48%	+51.67%	+65.00%	649B
ABBVIE INC.	+0.98%	-5.12%	+18.01%	+66.61%	440B
ROCHE HOLDING AG	0.00%	-0.09%	+29.37%	+37.42%	346B
NOVARTIS AG	+0.59%	-15.03%	+9.33%	+26.35%	263B
ASTRAZENECA PLC	-1.41%	-2.79%	-2.79%	+10.86%	250B
AMGEN INC.	+0.34%	-11.69%	+39.68%	+49.42%	213B
NOVO NORDISK A/S	-0.56%	-4.21%	-14.69%	-57.75%	201B
GILEAD SCIENCES, INC.	+0.24%	-2.59%	+25.89%	+89.16%	182B
Average	-0.66%	-2.06%	+23.03%	+41.90%	393.74B
Weighted average by Cap.	+0.39%	-2.39%	+32.28%	+56.24%